Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

67.02 +1.09 (+1.65%)
Streaming Delayed Price Updated: 9:52 AM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 121,428
Open 66.10
Bid (Size) 66.81 (400)
Ask (Size) 67.11 (100)
Prev. Close 65.93
Today's Range 65.50 - 67.09
52wk Range 9.570 - 76.76
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? ↗
Arrowhead Pharmaceuticals, a leader in RNAi therapeutics, reported a significant insider sale amid a year of exceptional stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value
The tech-heavy Nasdaq Composite faced a stark reversal on January 8, 2026, as a wave of profit-taking in high-flying artificial intelligence stocks, led by Nvidia (NASDAQ: NVDA), dragged the index... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks

Performance

YTD
-1.1%
-1.1%
1 Month
-2.1%
-2.1%
3 Month
+84.9%
+84.9%
6 Month
+260.1%
+260.1%
1 Year
+254.4%
+254.4%

More News

Read More
News headline image
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗
Via Stocktwits
News headline image
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Did ARWR Stock Surge Over 15% Pre-Market Today? ↗
Via Stocktwits
News headline image
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today ↗
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval ↗
Via Chartmill
News headline image
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
Via Benzinga

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 67.02
When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 01/13/26 09:52 AM ET
What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 7.09B
How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
Arrowhead Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.